BrightGene Bio-medical Technology(SH:688166) Xin Lang Cai Jing·2025-10-31 02:20Group 1 - The core viewpoint of the news is that BoRui Pharmaceutical (688166.SH) has reported its Q3 2025 results, highlighting the institutional investor landscape and changes in shareholding [1] - As of October 30, 2025, a total of 18 institutional investors hold shares in BoRui Pharmaceutical, with a combined holding of 65.7755 million shares, representing 15.55% of the total share capital [1] - The top ten institutional investors collectively hold 15.48% of the shares, which is a decrease of 1.36 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, three public funds increased their holdings, including the Innovation Drug ETF and the Penghua and Jiashi Shanghai Stock Exchange STAR Market Biomedicine ETFs, with a slight increase in the proportion of holdings [2] - Two public funds decreased their holdings compared to the previous quarter, including the STAR Market Medical ETF, with a slight decrease in the proportion of holdings [2] - Seven new public funds were disclosed this period, including the Guotai STAR Market Innovation Drug ETF and several index-enhanced funds [2] - A total of 158 public funds were not disclosed in this period, including various ETFs and enhanced bond funds [2] - One foreign fund, Hong Kong Central Clearing Limited, increased its holdings by 1.29% compared to the previous period [2]